Literature DB >> 7738190

Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.

D A Purcell-Huynh1, R V Farese, D F Johnson, L M Flynn, V Pierotti, D L Newland, M F Linton, D A Sanan, S G Young.   

Abstract

We previously generated transgenic mice expressing human apolipoprotein (apo-) B and demonstrated that the plasma of chow-fed transgenic animals contained markedly increased amounts of LDL (Linton, M. F., R. V. Farese, Jr., G. Chiesa, D. S. Grass, P. Chin, R. E. Hammer, H. H. Hobbs, and S. G. Young 1992. J. Clin. Invest. 92:3029-3037). In this study, we fed groups of transgenic and nontransgenic mice either a chow diet or a diet high in fat (16%) and cholesterol (1.25%). Lipid and lipoprotein levels were assessed, and after 18 wk of diet, the extent of aortic atherosclerotic lesions in each group of animals was quantified. Compared with the female transgenic mice on the chow diet, female transgenic mice on the high-fat diet had higher plasma levels of cholesterol (312 +/- 17 vs 144 +/- 7 mg/dl; P < 0.0001) and human apo-B (120 +/- 8 vs 84 +/- 3 mg/dl; P < 0.0001). The higher human apo-B levels were due to increased plasma levels of human apo-B48; the human apo-B100 levels did not differ in animals on the two diets. In mice on the high-fat diet, most of the human apo-B48 and apo-B100 was found in LDL-sized particles. Compared with nontransgenic mice on the high-fat diet, the transgenic animals on the high-fat diet had significantly increased levels of total cholesterol (312 +/- 17 vs 230 +/- 19 mg/dl; P < 0.0001) and non-HDL cholesterol (283 +/- 17 vs 193 +/- 19 mg/dl; P < 0.0001). The extent of atherosclerotic lesion development within the ascending aorta was quantified by measuring total lesion area in 60 progressive sections, using computer-assisted image analysis. Neither the chow-fed transgenic mice nor the chow-fed nontransgenic mice had significant atherosclerotic lesions. Nontransgenic animals on the high-fat diet had relatively small atherosclerotic lesions (< 15,000 microns 2/section), almost all of which were confined to the proximal 400 microns of the aorta near the aortic valve. In contrast, transgenic animals on the high-fat diet had extensive atherosclerotic lesions (> 160,000 microns 2/section) that were widely distributed throughout the proximal 1,200 microns of the aorta. Thus, human apo-B expression, in the setting of a diet rich in fats, causes severe atherosclerosis in mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738190      PMCID: PMC295837          DOI: 10.1172/JCI117915

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Apolipoprotein B mRNA editing. Direct determination of the edited base and occurrence in non-apolipoprotein B-producing cell lines.

Authors:  K Boström; Z Garcia; K S Poksay; D F Johnson; A J Lusis; T L Innerarity
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

2.  Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice.

Authors:  B Paigen; B Y Ishida; J Verstuyft; R B Winters; D Albee
Journal:  Arteriosclerosis       Date:  1990 Mar-Apr

3.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells.

Authors:  J A Piedrahita; S H Zhang; J R Hagaman; P M Oliver; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

4.  Synthetic low and high fat diets for the study of atherosclerosis in the mouse.

Authors:  P M Nishina; J Verstuyft; B Paigen
Journal:  J Lipid Res       Date:  1990-05       Impact factor: 5.922

Review 5.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

Authors:  T L Innerarity; R W Mahley; K H Weisgraber; T P Bersot; R M Krauss; G L Vega; S M Grundy; W Friedl; J Davignon; B J McCarthy
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

6.  Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H.

Authors:  B Y Ishida; P J Blanche; A V Nichols; M Yashar; B Paigen
Journal:  J Lipid Res       Date:  1991-04       Impact factor: 5.922

7.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

8.  Hepatic ACAT activity in African green monkeys is highly correlated to plasma LDL cholesteryl ester enrichment and coronary artery atherosclerosis.

Authors:  T P Carr; J S Parks; L L Rudel
Journal:  Arterioscler Thromb       Date:  1992-11

9.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

Authors:  E M Rubin; R M Krauss; E A Spangler; J G Verstuyft; S M Clift
Journal:  Nature       Date:  1991-09-19       Impact factor: 49.962

10.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

View more
  43 in total

1.  Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.

Authors:  M Raabe; M M Véniant; M A Sullivan; C H Zlot; J Björkegren; L B Nielsen; J S Wong; R L Hamilton; S G Young
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Increased atherosclerosis in hyperlipidemic mice deficient in alpha -tocopherol transfer protein and vitamin E.

Authors:  Y Terasawa; Z Ladha; S W Leonard; J D Morrow; D Newland; D Sanan; L Packer; M G Traber; R V Farese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  High-resolution association mapping of atherosclerosis loci in mice.

Authors:  Brian J Bennett; Luz Orozco; Emrah Kostem; Ayca Erbilgin; Marchien Dallinga; Isaac Neuhaus; Bo Guan; Xuping Wang; Eleazar Eskin; Aldons J Lusis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

4.  Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.

Authors:  M M Véniant; V Pierotti; D Newland; C M Cham; D A Sanan; R L Walzem; S G Young
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine.

Authors:  S G Young; C M Cham; R E Pitas; B J Burri; A Connolly; L Flynn; A S Pappu; J S Wong; R L Hamilton; R V Farese
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

Authors:  S H Zhang; R L Reddick; E Avdievich; L K Surles; R G Jones; J B Reynolds; S H Quarfordt; N Maeda
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

7.  Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.

Authors:  S Bellosta; R W Mahley; D A Sanan; J Murata; D L Newland; J M Taylor; R E Pitas
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Animal models of ischemic stroke. Part one: modeling risk factors.

Authors:  Marco Bacigaluppi; Giancarlo Comi; Dirk M Hermann
Journal:  Open Neurol J       Date:  2010-06-15

9.  ApoE-/- PGC-1α-/- mice display reduced IL-18 levels and do not develop enhanced atherosclerosis.

Authors:  Sokrates Stein; Christine Lohmann; Christoph Handschin; Elin Stenfeldt; Jan Borén; Thomas F Lüscher; Christian M Matter
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

10.  Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice.

Authors:  Omar M Khan; Murali K Akula; Kristina Skålen; Christin Karlsson; Marcus Ståhlman; Stephen G Young; Jan Borén; Martin O Bergo
Journal:  Circulation       Date:  2013-01-18       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.